A Phase 1 interventional study of 14C Epaminurad Oral Solution in Healthy Male Adults, sponsored by JW Pharmaceutical. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects
The following blood, urine and faecal samples will be collected, and assessments performed, at specified time points
JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Healthy volunteers
Exclusion Criteria:
1. Subjects does not meet the Inclusion Criteria
Drug: 14C Epaminurad Oral Solution
Subjects will receive a single administration of 14C Epaminurad Oral Solution
Mass balance recovery of total radioactivity in all excreta (urine and faeces)
Collection of plasma, urine and faeces samples during time frame point
Time frame: Baseline to Day 8
Metabolite profling and structural identification
Collection of plasma, urine and faeces samples during time frame point
Time frame: Baseline to Day 8
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Sep 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.